EGFR is frequently overexpressed in a variety of tumors (Sigismund et al., 2018), and activating mutations of EGFR, RAS, and RAF are the most significant oncogenic drivers in many malignancies, including lung (Chevallier et al., 2021), colorectal (Cancer Genome Atlas Network, 2012), pancreatic (Qian et al., 2020), and skin (Hodis et al., 2012) cancers. This evidence concerns the gene EGFR and cancer.